Raras
Buscar doenças, sintomas, genes...
Doença do metabolismo das purinas ou pirimidinas
ORPHA:79224DOENÇA RARA

Metabolismo é o conjunto de transformações que as substâncias químicas sofrem no interior dos organismos vivos. A expressão metabolismo celular é usada em referência ao conjunto de todas as reações químicas que ocorrem nas células. Estas reações são responsáveis pelos processos de síntese e degradação dos nutrientes na célula e constituem a base da vida, permitindo o crescimento e reprodução das células, mantendo as suas estruturas e adequando respostas aos seus ambientes.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença rara que afeta o metabolismo de purinas/pirimidinas, causando arreflexia, anormalidades do neurodesenvolvimento, lúpus, imunodeficiência e polineuropatia. Pode manifestar-se como paralisia cerebral, paraparesia espástica, infecções gastrointestinais e neoplasias.

🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
80 sintomas
🫘
Rins
67 sintomas
💪
Músculos
48 sintomas
📏
Crescimento
44 sintomas
🫃
Digestivo
42 sintomas
👁️
Olhos
27 sintomas

+ 333 sintomas em outras categorias

Características mais comuns

Arreflexia
Assimetria facial
Anormalidade do neurodesenvolvimento
Lúpus eritematoso sistêmico
Paralisia cerebral
Anormalidade da função motora central
775sintomas
Sem dados (775)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 775 características clínicas mais associadas, ordenadas por frequência.

ArreflexiaAreflexia
Assimetria facialHP:6000113
Anormalidade do neurodesenvolvimentoNeurodevelopmental abnormality
Lúpus eritematoso sistêmicoSystemic lupus erythematosus
Paralisia cerebralCerebral palsy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1
Últimos 10 anos200publicações
Pico2026195 papers
Linha do tempo
2025Hoje · 2026🧪 1998Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

53 genes identificados com associação a esta condição.

PDX1Pancreas/duodenum homeobox protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Activates insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 gene transcription. Particularly involved in glucose-dependent regulation of insulin gene transcription. As part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Binds preferentiall

LOCALIZAÇÃO

NucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (5)
Regulation of gene expression in beta cellsRegulation of gene expression in early pancreatic precursor cellsDevelopmental Lineage of Multipotent Pancreatic Progenitor CellsDevelopmental Lineage of Pancreatic Ductal CellsDevelopmental Lineage of Pancreatic Acinar Cells
MECANISMO DE DOENÇA

Pancreatic agenesis 1

A disease characterized by isolated hypoplasia or agenesis of the pancreas, pancreatic beta-cell failure resulting in neonatal insulin-dependent diabetes mellitus, and exocrine pancreatic insufficiency.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pâncreas
9.2 TPM
Linfócitos
0.5 TPM
Testículo
0.2 TPM
Fígado
0.2 TPM
Estômago
0.1 TPM
OUTRAS DOENÇAS (6)
maturity-onset diabetes of the young type 4pancreatic agenesis 1pancreatic agenesismaturity-onset diabetes of the young
HGNC:6107UniProt:P52945
ADSLAdenylosuccinate lyaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes two non-sequential steps in de novo AMP synthesis: converts (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate (SAICAR) to fumarate plus 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide, and thereby also contributes to de novo IMP synthesis, and converts succinyladenosine monophosphate (SAMP) to AMP and fumarate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Purine ribonucleoside monophosphate biosynthesis
MECANISMO DE DOENÇA

Adenylosuccinase deficiency

An autosomal recessive disorder characterized by the accumulation in the body fluids of succinylaminoimidazole-carboxamide riboside (SAICA-riboside) and succinyladenosine (S-Ado). Most children display marked psychomotor delay, often accompanied by epilepsy or autistic features, or both, although some patients may be less profoundly retarded. Occasionally, growth retardation and muscular wasting are also present.

OUTRAS DOENÇAS (1)
adenylosuccinate lyase deficiency
HGNC:291UniProt:P30566
AMPD1AMP deaminase 1Candidate gene tested inTolerante
FUNÇÃO

AMP deaminase plays a critical role in energy metabolism

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Myopathy due to myoadenylate deaminase deficiency

A metabolic disorder resulting in exercise-related myopathy. It is characterized by exercise-induced muscle aches, cramps, and early fatigue.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
myopathy due to myoadenylate deaminase deficiencyadenosine monophosphate deaminase deficiency
HGNC:468UniProt:P23109
ALDOAFructose-bisphosphate aldolase ACandidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible conversion of beta-D-fructose 1,6-bisphosphate (FBP) into two triose phosphate and plays a key role in glycolysis and gluconeogenesis (PubMed:14766013). In addition, may also function as scaffolding protein (By similarity)

LOCALIZAÇÃO

Cytoplasm, myofibril, sarcomere, I bandCytoplasm, myofibril, sarcomere, M line

VIAS BIOLÓGICAS (2)
GlycolysisGluconeogenesis
MECANISMO DE DOENÇA

Glycogen storage disease 12

A metabolic disorder associated with increased hepatic glycogen and hemolytic anemia. It may lead to myopathy with exercise intolerance and rhabdomyolysis.

OUTRAS DOENÇAS (1)
glycogen storage disease due to aldolase A deficiency
HGNC:414UniProt:P04075
NT5C3ACytosolic 5'-nucleotidase 3ACandidate gene tested inTolerante
FUNÇÃO

Nucleotidase which shows specific activity towards cytidine monophosphate (CMP) and 7-methylguanosine monophosphate (m(7)GMP) (PubMed:24603684). CMP seems to be the preferred substrate (PubMed:15968458)

LOCALIZAÇÃO

CytoplasmEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Pyrimidine catabolism
MECANISMO DE DOENÇA

P5N deficiency

Autosomal recessive condition causing hemolytic anemia characterized by marked basophilic stippling and the accumulation of high concentrations of pyrimidine nucleotides within the erythrocyte. It is implicated in the anemia of lead poisoning and is possibly associated with learning difficulties.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
106.4 TPM
Músculo esquelético
31.6 TPM
Cervix Ectocervix
28.5 TPM
Vagina
27.3 TPM
Útero
26.9 TPM
OUTRAS DOENÇAS (1)
hemolytic anemia due to pyrimidine 5' nucleotidase deficiency
HGNC:17820UniProt:Q9H0P0
TK2Thymidine kinase 2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix (PubMed:11687801, PubMed:9989599). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK (PubMed:9989599). Widely used as target of antiviral and chemotherapeutic agents (PubMed:9989599)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Pyrimidine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 2

A disorder due to mitochondrial dysfunction characterized by childhood onset of muscle weakness associated with depletion of mtDNA in skeletal muscle. There is wide clinical variability; some patients have onset in infancy and show a rapidly progressive course with early death due to respiratory failure, whereas others have later onset of a slowly progressive myopathy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
39.7 TPM
Nervo tibial
33.3 TPM
Tecido adiposo
32.0 TPM
Ovário
28.1 TPM
Fibroblastos
26.0 TPM
OUTRAS DOENÇAS (3)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3mitochondrial DNA depletion syndrome, myopathic formautosomal recessive progressive external ophthalmoplegia
HGNC:11831UniProt:O00142
APPL1DCC-interacting protein 13-alphaCandidate gene tested inRestrito
FUNÇÃO

Multifunctional adapter protein that binds to various membrane receptors, nuclear factors and signaling proteins to regulate many processes, such as cell proliferation, immune response, endosomal trafficking and cell metabolism (PubMed:10490823, PubMed:15016378, PubMed:19661063, PubMed:26073777, PubMed:26583432). Regulates signaling pathway leading to cell proliferation through interaction with RAB5A and subunits of the NuRD/MeCP1 complex (PubMed:15016378). Functions as a positive regulator of i

LOCALIZAÇÃO

Early endosome membraneNucleusCytoplasmEndosomeCell projection, ruffleCytoplasmic vesicle, phagosome

VIAS BIOLÓGICAS (1)
Caspase activation via Dependence Receptors in the absence of ligand
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 14

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

OUTRAS DOENÇAS (2)
maturity-onset diabetes of the youngmaturity-onset diabetes of the young type 14
HGNC:24035UniProt:Q9UKG1
NARS2Asparaginyl-tRNA synthetaseCandidate gene tested inTolerante
FUNÇÃO

Mitochondrial aminoacyl-tRNA synthetase that catalyzes the specific attachment of the asparagine amino acid (aa) to the homologous transfer RNA (tRNA), further participating in protein synthesis (PubMed:25385316). The reaction occurs in a two steps: asparagine is first activated by ATP to form Asn-AMP and then transferred to the acceptor end of tRNA(Asn) (Probable)

LOCALIZAÇÃO

Mitochondrion matrixMitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 24

An autosomal recessive mitochondrial disorder with wide phenotypic variability. Some patients have a milder form affecting only skeletal muscle, whereas others may have a more severe disorder, reminiscent of Alpers syndrome. Alpers syndrome is a progressive neurodegenerative disorder that presents in infancy or early childhood and is characterized by diffuse degeneration of cerebral gray matter.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
24.4 TPM
Ovário
17.6 TPM
Fibroblastos
16.6 TPM
Cervix Endocervix
16.3 TPM
Cervix Ectocervix
15.3 TPM
OUTRAS DOENÇAS (4)
combined oxidative phosphorylation defect type 24hearing loss, autosomal recessive 94DEND syndromehearing loss, autosomal recessive
HGNC:26274UniProt:Q96I59
UPB1Beta-ureidopropionaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes a late step in pyrimidine degradation (PubMed:22525402, PubMed:24526388). Converts N-carbamoyl-beta-alanine (3-ureidopropanoate) into beta-alanine, ammonia and carbon dioxide (PubMed:10415095, PubMed:10542323, PubMed:11508704, PubMed:22525402, PubMed:24526388, PubMed:29976570). Likewise, converts N-carbamoyl-beta-aminoisobutyrate (3-ureidoisobutyrate) into beta-aminoisobutyrate, ammonia and carbon dioxide (Probable)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Pyrimidine catabolism
MECANISMO DE DOENÇA

Beta-ureidopropionase deficiency

An inborn error of metabolism due to a defect in pyrimidine degradation. It is characterized by muscular hypotonia, dystonic movements, scoliosis, microcephaly and severe developmental delay. Patients show strongly elevated levels of N-carbamyl-beta-alanine and N-carbamyl-beta-aminoisobutyric acid in plasma, cerebrospinal fluid and urine.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
50.1 TPM
Rim - Córtex
7.2 TPM
Testículo
3.5 TPM
Rim - Medula
3.0 TPM
Linfócitos
2.8 TPM
OUTRAS DOENÇAS (1)
beta-ureidopropionase deficiency
HGNC:16297UniProt:Q9UBR1
RRM2BRibonucleoside-diphosphate reductase subunit M2 BCandidate gene tested inTolerante
FUNÇÃO

Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesInterconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 8A

A disorder due to mitochondrial dysfunction characterized by various combinations of neonatal hypotonia, neurological deterioration, respiratory distress, lactic acidosis, and renal tubulopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.2 TPM
Tireoide
33.1 TPM
Fibroblastos
25.4 TPM
Aorta
22.0 TPM
Pulmão
20.7 TPM
OUTRAS DOENÇAS (7)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunctionmitochondrial DNA depletion syndrome 8aKearns-Sayre syndrome
HGNC:17296UniProt:Q7LG56
AMPD3AMP deaminase 3Candidate gene tested inTolerante
FUNÇÃO

AMP deaminase plays a critical role in energy metabolism

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Adenosine monophosphate deaminase deficiency erythrocyte type

A metabolic disorder due to lack of activity of the erythrocyte isoform of AMP deaminase. It is a clinically asymptomatic condition characterized by a 50% increase in steady-state levels of ATP in affected cells. Individuals with complete deficiency of erythrocyte AMP deaminase are healthy and have no hematologic disorders.

OUTRAS DOENÇAS (2)
obsolete erythrocyte AMP deaminase deficiencyadenosine monophosphate deaminase deficiency
HGNC:470UniProt:Q01432
ABCC8ATP-binding cassette sub-family C member 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulator subunit of pancreatic ATP-sensitive potassium channel (KATP), playing a major role in the regulation of insulin release. In pancreatic cells, it forms KATP channels with KCNJ11; KCNJ11 forms the channel pore while ABCC8 is required for activation and regulation

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Regulation of insulin secretionATP sensitive Potassium channels
MECANISMO DE DOENÇA

Leucine-induced hypoglycemia

Rare cause of hypoglycemia and is described as a condition in which symptomatic hypoglycemia is provoked by high protein feedings. Hypoglycemia is also elicited by administration of oral or intravenous infusions of a single amino acid, leucine.

OUTRAS DOENÇAS (12)
hyperinsulinemic hypoglycemia, familial, 1diabetes mellitus, transient neonatal, 2diabetes mellitus, permanent neonatal 3hypoglycemia, leucine-induced
HGNC:59UniProt:Q09428
HK1Hexokinase-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the phosphorylation of various hexoses, such as D-glucose, D-glucosamine, D-fructose, D-mannose and 2-deoxy-D-glucose, to hexose 6-phosphate (D-glucose 6-phosphate, D-glucosamine 6-phosphate, D-fructose 6-phosphate, D-mannose 6-phosphate and 2-deoxy-D-glucose 6-phosphate, respectively) (PubMed:1637300, PubMed:25316723, PubMed:27374331). Does not phosphorylate N-acetyl-D-glucosamine (PubMed:27374331). Mediates the initial step of glycolysis by catalyzing phosphorylation of D-glucose to

LOCALIZAÇÃO

Mitochondrion outer membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
GlycolysisSynthesis of GDP-mannose
MECANISMO DE DOENÇA

Anemia, congenital, non-spherocytic hemolytic, 5

An autosomal recessive disorder characterized by hemolytic anemia as the predominant clinical feature, and decreased red cell hexokinase activity.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
153.8 TPM
Cerebelo
139.0 TPM
Esôfago - Mucosa
123.5 TPM
Skin Sun Exposed Lower leg
114.2 TPM
Aorta
113.3 TPM
OUTRAS DOENÇAS (4)
neurodevelopmental disorder with visual defects and brain anomaliesretinitis pigmentosa 79non-spherocytic hemolytic anemia due to hexokinase deficiencyCharcot-Marie-Tooth disease type 4G
HGNC:4922UniProt:P19367
GPIGlucose-6-phosphate isomeraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Isomerase that catalyzes the conversion of alpha-D-glucose-6-phosphate to beta-D-fructose-6-phosphate, the second step in glycolysis, and the reverse reaction in gluconeogenesis, within the cytoplasm (PubMed:28803808). Also shows C2-epimerase activity, interconverting D-glucose-6-phosphate (G6P) and D-mannose-6-phosphate (M6P) (By similarity). Also displays anomerase activity, interconverting alpha and beta-anomeric forms of G6P, D-fructose-6-phosphate and M6P (By similarity). In addition to its

LOCALIZAÇÃO

CytoplasmSecreted

VIAS BIOLÓGICAS (3)
GlycolysisGluconeogenesisTP53 Regulates Metabolic Genes
MECANISMO DE DOENÇA

Anemia, congenital, non-spherocytic hemolytic, 4

An autosomal recessive form of anemia in which there is no abnormal hemoglobin or spherocytosis. It is caused by glucose phosphate isomerase deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
398.0 TPM
Cérebro - Hemisfério cerebelar
310.4 TPM
Cerebelo
301.6 TPM
Brain Frontal Cortex BA9
224.2 TPM
Glândula adrenal
217.7 TPM
OUTRAS DOENÇAS (1)
hemolytic anemia due to glucophosphate isomerase deficiency
HGNC:4458UniProt:P06744
PKLRPyruvate kinase PKLRDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
Pyruvate metabolismGlycolysisChREBP activates metabolic gene expression
MECANISMO DE DOENÇA

Pyruvate kinase hyperactivity

Autosomal dominant phenotype characterized by increase of red blood cell ATP.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
34.4 TPM
Rim - Córtex
8.2 TPM
Intestino delgado
3.3 TPM
Cérebro - Hemisfério cerebelar
2.7 TPM
Cerebelo
2.2 TPM
OUTRAS DOENÇAS (2)
pyruvate kinase hyperactivitypyruvate kinase deficiency of red cells
HGNC:9020UniProt:P30613
ATICBifunctional purine biosynthesis protein ATICDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme that catalyzes the last two steps of purine biosynthesis (PubMed:11948179, PubMed:14756554). Acts as a transformylase that incorporates a formyl group to the AMP analog AICAR (5-amino-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamide) to produce the intermediate formyl-AICAR (FAICAR) (PubMed:10985775, PubMed:11948179, PubMed:9378707). Can use both 10-formyldihydrofolate and 10-formyltetrahydrofolate as the formyl donor in this reaction (PubMed:10985775). Also catalyzes the

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Purine ribonucleoside monophosphate biosynthesis
MECANISMO DE DOENÇA

AICA-ribosuria due to ATIC deficiency

A neurologically devastating inborn error of purine biosynthesis. Patients excrete massive amounts of AICA-riboside in the urine and accumulate AICA-ribotide and its derivatives in erythrocytes and fibroblasts. Clinical features include profound intellectual disability, epilepsy, dysmorphic features and congenital blindness. AICAR inheritance is autosomal recessive.

OUTRAS DOENÇAS (1)
AICA-ribosiduria
HGNC:794UniProt:P31939
PNPPancreatic polypeptide prohormoneDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hormone secreted by pancreatic cells that acts as a regulator of pancreatic and gastrointestinal functions probably by signaling through the G protein-coupled receptor NPY4R2

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (3)
Purine salvagePurine catabolismRibavirin ADME
EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
116.3 TPM
Esôfago - Mucosa
84.0 TPM
Linfócitos
81.9 TPM
Rim - Córtex
74.0 TPM
Adipose Visceral Omentum
64.3 TPM
OUTRAS DOENÇAS (1)
purine nucleoside phosphorylase deficiency
HGNC:7892UniProt:P01298
DPYSDihydropyrimidinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Pyrimidine catabolism
MECANISMO DE DOENÇA

Dihydropyrimidinase deficiency

An autosomal recessive disorder of pyrimidine metabolism characterized by dihydropyrimidinuria. It is associated with a variable clinical phenotype characterized by epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy. Most patients are, however, asymptomatic.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
132.8 TPM
Rim - Córtex
39.1 TPM
Rim - Medula
12.8 TPM
Adipose Visceral Omentum
6.6 TPM
Glândula adrenal
6.2 TPM
OUTRAS DOENÇAS (1)
dihydropyrimidinuria
HGNC:3013UniProt:Q14117
GATA1Erythroid transcription factorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional activator or repressor which serves as a general switch factor for erythroid development (PubMed:35030251). It binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and of other genes expressed in erythroid cells. Activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2 and HMBS (PubMed:24245781)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functionRUNX1 regulates transcription of genes involved in differentiation of HSCsFactors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

X-linked dyserythropoietic anemia and thrombocytopenia

Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
25.8 TPM
Pulmão
3.7 TPM
Testículo
3.6 TPM
Baço
1.9 TPM
Pituitária
0.8 TPM
OUTRAS DOENÇAS (10)
transient myeloproliferative syndromethrombocytopenia, X-linked, with or without dyserythropoietic anemiahemolytic anemia due to erythrocyte adenosine deaminase overproductionX-linked dyserythropoetic anemia with abnormal platelets and neutropenia
HGNC:4170UniProt:P15976
APRTAdenine phosphoribosyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Adenine phosphoribosyltransferase deficiency

An enzymatic deficiency that can lead to urolithiasis and renal failure. Patients have 2,8-dihydroxyadenine (DHA) urinary stones.

OUTRAS DOENÇAS (1)
adenine phosphoribosyltransferase deficiency
HGNC:626UniProt:P07741
PFKMATP-dependent 6-phosphofructokinase, muscle typeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Glycolysis
MECANISMO DE DOENÇA

Glycogen storage disease 7

A metabolic disorder characterized by exercise intolerance with associated nausea and vomiting, muscle cramping, exertional myopathy and compensated hemolysis. Short bursts of intense activity are particularly difficult. Severe muscle cramps and myoglobinuria develop after vigorous exercise.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
501.6 TPM
Coração - Ventrículo esquerdo
126.7 TPM
Cérebro - Hemisfério cerebelar
110.7 TPM
Cerebelo
102.2 TPM
Coração - Átrio
83.2 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease VII
HGNC:8877UniProt:P08237
DPYDDihydropyrimidine dehydrogenase [NADP(+)]Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in pyrimidine base degradation (PubMed:1512248). Catalyzes the reduction of uracil and thymine (PubMed:1512248). Also involved the degradation of the chemotherapeutic drug 5-fluorouracil (PubMed:1512248)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Pyrimidine catabolism
MECANISMO DE DOENÇA

Dihydropyrimidine dehydrogenase deficiency

A metabolic disorder with large phenotypic variability, ranging from no symptoms to a convulsive disorder with motor and intellectual disability. It is characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
43.0 TPM
Pulmão
29.6 TPM
Adipose Visceral Omentum
24.0 TPM
Tecido adiposo
23.3 TPM
Cervix Ectocervix
23.0 TPM
OUTRAS DOENÇAS (2)
dihydropyrimidine dehydrogenase deficiency1p21.3 microdeletion syndrome
HGNC:3012UniProt:Q12882
PGK1Phosphoglycerate kinase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes one of the two ATP producing reactions in the glycolytic pathway via the reversible conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate (PubMed:30323285, PubMed:7391028). Both L- and D- forms of purine and pyrimidine nucleotides can be used as substrates, but the activity is much lower on pyrimidines (PubMed:18463139). In addition to its role as a glycolytic enzyme, it seems that PGK1 acts as a polymerase alpha cofactor protein (primer recognition protein) (PubMed:2324090). Acts

LOCALIZAÇÃO

Cytoplasm, cytosolMitochondrion matrix

VIAS BIOLÓGICAS (3)
GlycolysisGluconeogenesisManipulation of host energy metabolism
MECANISMO DE DOENÇA

Phosphoglycerate kinase 1 deficiency

A condition with a highly variable clinical phenotype that includes hemolytic anemia, rhabdomyolysis, myopathy and neurologic involvement. Patients can express one or more of these manifestations, and some affected individuals develop parkinsonian symptoms.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
714.5 TPM
Fibroblastos
373.9 TPM
Sangue
235.7 TPM
Esôfago - Mucosa
168.6 TPM
Esôfago - Muscular
150.6 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease due to phosphoglycerate kinase 1 deficiency
HGNC:8896UniProt:P00558
HNF1BHepatocyte nuclear factor 1-betaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor that binds to the inverted palindrome 5'-GTTAATNATTAAC-3' (PubMed:17924661, PubMed:7900999). Binds to the FPC element in the cAMP regulatory unit of the PLAU gene (By similarity). Transcriptional activity is increased by coactivator PCBD1 (PubMed:24204001)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (6)
Nephron developmentRegulation of gene expression in early pancreatic precursor cellsRegulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cellsDevelopmental Lineage of Multipotent Pancreatic Progenitor CellsDevelopmental Lineage of Pancreatic Ductal Cells
MECANISMO DE DOENÇA

Renal cysts and diabetes syndrome

An autosomal dominant disorder comprising non-diabetic renal disease resulting from abnormal renal development, and diabetes, which in some cases occurs earlier than age 25 years and is thus consistent with a diagnosis of maturity-onset diabetes of the young (MODY5). The renal disease is highly variable and includes renal cysts, glomerular tufts, aberrant nephrogenesis, primitive tubules, irregular collecting systems, oligomeganephronia, enlarged renal pelves, abnormal calyces, small kidney, single kidney, horseshoe kidney, and hyperuricemic nephropathy. Affected individuals may also have abnormalities of the genital tract.

EXPRESSÃO TECIDUAL(Tecido-específico)
Rim - Medula
90.4 TPM
Rim - Córtex
53.5 TPM
Linfócitos
43.7 TPM
Pâncreas
23.0 TPM
Cólon transverso
14.9 TPM
OUTRAS DOENÇAS (11)
type 2 diabetes mellitusrenal cysts and diabetes syndromechromosome 17q12 deletion syndromerenal dysplasia, unilateral
HGNC:11630UniProt:P35680
MOCOSMolybdenum cofactor sulfuraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Sulfurates the molybdenum cofactor (PubMed:34356852). Sulfation of molybdenum is essential for xanthine dehydrogenase (XDH) and aldehyde oxidase (ADO) enzymes in which molybdenum cofactor is liganded by 1 oxygen and 1 sulfur atom in active form (PubMed:34356852). In vitro, the C-terminal domain is able to reduce N-hydroxylated prodrugs, such as benzamidoxime (PubMed:16973608)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Molybdenum cofactor biosynthesis
MECANISMO DE DOENÇA

Xanthinuria 2

A disorder characterized by excretion of very large amounts of xanthine in the urine and a tendency to form xanthine stones. Uric acid is strikingly diminished in serum and urine. In addition, XAN2 patients cannot metabolize allopurinol into oxypurinol due to dual deficiency of xanthine dehydrogenase and aldehyde oxidase.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
14.8 TPM
Ovário
14.3 TPM
Fibroblastos
12.6 TPM
Fígado
11.8 TPM
Esôfago - Mucosa
5.7 TPM
OUTRAS DOENÇAS (1)
xanthinuria type II
HGNC:18234UniProt:Q96EN8
UMODUromodulinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions in biogenesis and organization of the apical membrane of epithelial cells of the thick ascending limb of Henle's loop (TALH), where it promotes formation of complex filamentous gel-like structure that may play a role in the water barrier permeability (Probable). May serve as a receptor for binding and endocytosis of cytokines (IL-1, IL-2) and TNF (PubMed:3498215). Facilitates neutrophil migration across renal epithelia (PubMed:20798515) In the urine, may contribute to colloid osmotic p

LOCALIZAÇÃO

Apical cell membraneBasolateral cell membraneCell projection, cilium membraneSecreted

VIAS BIOLÓGICAS (1)
Asparagine N-linked glycosylation
MECANISMO DE DOENÇA

Tubulointerstitial kidney disease, autosomal dominant 1

A form of autosomal dominant tubulointerstitial kidney disease, a genetically heterogeneous disorder characterized by slowly progressive loss of kidney function, bland urinary sediment, hyperuricemia, absent or mildly increased albuminuria, lack of severe hypertension during the early stages, and normal or small kidneys on ultrasound. Renal histology shows variable abnormalities including interstitial fibrosis with tubular atrophy, microcystic dilatation of the tubules, thickening of tubular basement membranes, medullary cysts, and secondary glomerulosclerotic or glomerulocystic changes with abnormal glomerular tufting. There is significant variability, as well as incomplete penetrance.

EXPRESSÃO TECIDUAL(Tecido-específico)
Rim - Medula
2116.0 TPM
Rim - Córtex
190.5 TPM
Pâncreas
2.5 TPM
Testículo
0.9 TPM
Estômago
0.2 TPM
OUTRAS DOENÇAS (1)
familial juvenile hyperuricemic nephropathy type 1
HGNC:12559UniProt:P07911
HPRT1Hypoxanthine-guanine phosphoribosyltransferaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Purine salvageAzathioprine ADME
MECANISMO DE DOENÇA

Lesch-Nyhan syndrome

Characterized by complete lack of enzymatic activity that results in hyperuricemia, choreoathetosis, intellectual disability, and compulsive self-mutilation.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
128.5 TPM
Brain Frontal Cortex BA9
120.5 TPM
Testículo
116.1 TPM
Cérebro - Hemisfério cerebelar
78.0 TPM
Brain Anterior cingulate cortex BA24
66.1 TPM
OUTRAS DOENÇAS (2)
hypoxanthine guanine phosphoribosyltransferase partial deficiencyLesch-Nyhan syndrome
HGNC:5157UniProt:P00492
ITPAInosine triphosphate pyrophosphataseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triphosphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Purine catabolismRibavirin ADME
MECANISMO DE DOENÇA

Inosine triphosphate pyrophosphohydrolase deficiency

A common inherited condition characterized by the abnormal accumulation of inosine triphosphate in erythrocytes. It might have pharmacogenomic implications and be related to increased drug toxicity of purine analog drugs.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
76.1 TPM
Fibroblastos
66.5 TPM
Linfócitos
65.8 TPM
Cervix Ectocervix
56.4 TPM
Cervix Endocervix
55.9 TPM
OUTRAS DOENÇAS (2)
inosine triphosphatase deficiencydevelopmental and epileptic encephalopathy, 35
HGNC:6176UniProt:Q9BY32
LIG3DNA ligase 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Isoform 3 functions as a heterodimer with DNA-repair protein XRCC1 in the nucleus and can correct defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents. Isoform 1 is targeted to mitochondria, where it functions as a DNA ligase in mitochondrial base-excision DNA repair (PubMed:10207110, PubMed:24674627)

LOCALIZAÇÃO

MitochondrionNucleus

VIAS BIOLÓGICAS (5)
HDR through MMEJ (alt-NHEJ)Gap-filling DNA repair synthesis and ligation in TC-NERGap-filling DNA repair synthesis and ligation in GG-NERAPEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement PathwayResolution of AP sites via the single-nucleotide replacement pathway
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 20, MNGIE type

An autosomal recessive mitochondrial disorder characterized by severe gut dysmotility, muscle weakness and atrophy, neurological abnormalities including epilepsy, migraine, stroke-like episodes, learning difficulties or cognitive decline, and neurogenic bladder. Brain imaging usually shows diffuse leukoencephalopathy and may show cerebellar atrophy. Disease onset can range from infancy to the teenage years.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
31.8 TPM
Útero
24.9 TPM
Fallopian Tube
22.8 TPM
Cervix Endocervix
18.8 TPM
Ovário
18.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 20 (mngie type)mitochondrial neurogastrointestinal encephalomyopathy
HGNC:6600UniProt:P49916
GCKMitogen-activated protein kinase kinase kinase kinase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidi

LOCALIZAÇÃO

CytoplasmBasolateral cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (5)
GlycolysisRegulation of gene expression in beta cellsRegulation of Glucokinase by Glucokinase Regulatory ProteinDefective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
34.5 TPM
Cérebro - Hemisfério cerebelar
7.2 TPM
Cerebelo
7.1 TPM
Hipotálamo
6.5 TPM
Coração - Átrio
3.1 TPM
OUTRAS DOENÇAS (7)
type 2 diabetes mellitusmaturity-onset diabetes of the young type 2permanent neonatal diabetes mellitus 1monogenic diabetes
HGNC:4195UniProt:Q12851
ENO3Beta-enolaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Enolase that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis and the reverse reaction in gluconeogenesis. Appears to have a function in striated muscle development and regeneration

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
GluconeogenesisGlycolysis
MECANISMO DE DOENÇA

Glycogen storage disease 13

A metabolic disorder that results in exercise-induced myalgias, generalized muscle weakness and fatigability. It is characterized by increased serum creatine kinase and decreased enolase 3 activity. Dramatically reduced protein levels with focal sarcoplasmic accumulation of glycogen-beta particles are detected on ultrastructural analysis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
1974.4 TPM
Coração - Ventrículo esquerdo
171.2 TPM
Coração - Átrio
101.8 TPM
Fígado
35.9 TPM
Linfócitos
16.3 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease due to muscle beta-enolase deficiency
HGNC:3354UniProt:P13929
PGAM2Phosphoglycerate mutase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the interconversion of 3- and 2-phosphoglycerate with 2,3-bisphosphoglycerate as the primer of the reaction. Can also catalyze the interconversion of (2R)-2,3-bisphosphoglycerate and (2R)-3-phospho-glyceroyl phosphate, but with a reduced activity

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
GlycolysisGluconeogenesis
MECANISMO DE DOENÇA

Glycogen storage disease 10

A metabolic disorder characterized by myoglobinuria, increased serum creatine kinase levels, decreased phosphoglycerate mutase activity, myalgia, muscle pain, muscle cramps, exercise intolerance.

OUTRAS DOENÇAS (1)
glycogen storage disease due to phosphoglycerate mutase deficiency
HGNC:8889UniProt:P15259
CADDNA fragmentation factor subunit betaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Nuclease that induces DNA fragmentation and chromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Pyrimidine biosynthesis
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 50
HGNC:1424UniProt:O76075
LDHDD-lactate dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

The mitochondrial D-lactate dehydrogenase is a stereoselective dehydrogenase that targets a wide variety of D-2-hydroxyacids, particularly those with small to moderately sized hydrophobic groups attached to the C2 atom. It includes D-lactate which is generated in small amounts either endogenously through the methylglyoxal metabolism pathway or exogenously via intestinal bacterial activity and dietary intake. The dehydrogenase acts specifically on D-lactate, not on its stereoisomer L-lactate, and

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

D-lactic aciduria with gout

An autosomal recessive metabolic disorder characterized by D-lactic aciduria in the presence of normal plasma lactic acid.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
91.7 TPM
Coração - Ventrículo esquerdo
58.5 TPM
Músculo esquelético
47.1 TPM
Ovário
39.4 TPM
Rim - Córtex
31.4 TPM
OUTRAS DOENÇAS (1)
lactic aciduria due to D-lactic acid
HGNC:HGNC:19708UniProt:Q86WU2
NEUROD1Neurogenic differentiation factor 1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Acts as a transcriptional activator: mediates transcriptional activation by binding to E box-containing promoter consensus core sequences 5'-CANNTG-3'. Associates with the p300/CBP transcription coactivator complex to stimulate transcription of the secretin gene as well as the gene encoding the cyclin-dependent kinase inhibitor CDKN1A. Contributes to the regulation of several cell differentiation pathways, like those that promote the formation of early retinal ganglion cells, inner ear sensory n

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
Regulation of gene expression in beta cellsRegulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 6

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
306.4 TPM
Cerebelo
215.4 TPM
Hipocampo
4.2 TPM
Brain Frontal Cortex BA9
3.6 TPM
Córtex cerebral
3.4 TPM
OUTRAS DOENÇAS (3)
maturity-onset diabetes of the young type 6maturity-onset diabetes of the youngtype 2 diabetes mellitus
HGNC:7762UniProt:Q13562
HNF1AHepatocyte nuclear factor 1-alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver (By similarity). Binds to the inverted palindrome 5'-GTTAATNATTAAC-3' (PubMed:10966642, PubMed:12453420). Activates the transcription of CYP1A2, CYP2E1 and CYP3A11 (By similarity) (Microbial infection) Plays a crucial role for hepatitis B virus gene transcription and DNA replication. Mechanistically, synergistically cooperates with NR5A2 to up-regulate the

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Regulation of gene expression in beta cells
MECANISMO DE DOENÇA

Hepatic adenomas familial

Rare benign liver tumors of presumable epithelial origin that develop in an otherwise normal liver. Hepatic adenomas may be single or multiple. They consist of sheets of well-differentiated hepatocytes that contain fat and glycogen and can produce bile. Bile ducts or portal areas are absent. Kupffer cells, if present, are reduced in number and are non-functional. Conditions associated with adenomas are insulin-dependent diabetes mellitus and glycogen storage diseases (types 1 and 3).

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
8.7 TPM
Intestino delgado
6.3 TPM
Rim - Córtex
5.3 TPM
Cólon transverso
4.3 TPM
Estômago
4.1 TPM
OUTRAS DOENÇAS (11)
maturity-onset diabetes of the young type 3nonpapillary renal cell carcinomahepatic adenomas, familialtype 1 diabetes mellitus 20
HGNC:11621UniProt:P20823
LDHAL-lactate dehydrogenase A chainDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Pyruvate metabolismRegulation of pyruvate metabolism
MECANISMO DE DOENÇA

Glycogen storage disease 11

A metabolic disorder that results in exertional myoglobinuria, pain, cramps and easy fatigue.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1357.2 TPM
Fibroblastos
1101.5 TPM
Artéria tibial
510.3 TPM
Aorta
482.4 TPM
Artéria coronária
397.3 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease due to lactate dehydrogenase M-subunit deficiency
HGNC:6535UniProt:P00338
PRPS1Ribose-phosphate pyrophosphokinase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
5-Phosphoribose 1-diphosphate biosynthesis
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.0 TPM
Cérebro - Hemisfério cerebelar
64.3 TPM
Fibroblastos
58.6 TPM
Cerebelo
51.2 TPM
Tireoide
51.1 TPM
OUTRAS DOENÇAS (8)
phosphoribosylpyrophosphate synthetase superactivityCharcot-Marie-Tooth disease X-linked recessive 5Arts syndromehearing loss, X-linked 1
HGNC:9462UniProt:P60891
POLGDNA polymerase subunit gamma-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
DGUOKDeoxyguanosine kinase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine (PubMed:11687801, PubMed:17073823, PubMed:23043144, PubMed:8692979, PubMed:8706825). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. Phosphorylates certain nucleoside analogs (By similarity). Widely used as target of antiviral and chemotherapeutic agents

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 3

A disorder due to mitochondrial dysfunction characterized by onset in infancy of progressive liver failure, hypoglycemia, increased lactate in body fluids, and neurologic abnormalities including hypotonia, encephalopathy, peripheral neuropathy. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes and mtDNA depletion.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.1 TPM
Pituitária
72.5 TPM
Ovário
63.9 TPM
Aorta
61.4 TPM
Testículo
61.4 TPM
OUTRAS DOENÇAS (3)
mitochondrial DNA depletion syndrome 3 (hepatocerebral type)portal hypertension, noncirrhotic, 1progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4
HGNC:2858UniProt:Q16854
TYMPThymidine phosphorylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Pyrimidine salvagePyrimidine catabolism
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 1, MNGIE type

A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
330.6 TPM
Pulmão
260.6 TPM
Baço
215.3 TPM
Tecido adiposo
140.0 TPM
Adipose Visceral Omentum
116.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 1mitochondrial neurogastrointestinal encephalomyopathy
HGNC:3148UniProt:P19971
TPI1Triosephosphate isomeraseDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Triosephosphate isomerase is an extremely efficient metabolic enzyme that catalyzes the interconversion between dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde-3-phosphate (G3P) in glycolysis and gluconeogenesis It is also responsible for the non-negligible production of methylglyoxal a reactive cytotoxic side-product that modifies and can alter proteins, DNA and lipids

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
GlycolysisGluconeogenesis
MECANISMO DE DOENÇA

Triosephosphate isomerase deficiency

An autosomal recessive multisystem disorder characterized by congenital hemolytic anemia, progressive neuromuscular dysfunction, susceptibility to bacterial infection, and cardiomyopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1176.5 TPM
Fibroblastos
855.2 TPM
Esôfago - Mucosa
517.8 TPM
Brain Frontal Cortex BA9
466.6 TPM
Cerebelo
441.8 TPM
OUTRAS DOENÇAS (1)
triosephosphate isomerase deficiency
HGNC:12009UniProt:P60174
XDHXanthine dehydrogenase/oxidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro)

LOCALIZAÇÃO

CytoplasmPeroxisomeSecreted

VIAS BIOLÓGICAS (3)
Purine catabolismAzathioprine ADMEButyrophilin (BTN) family interactions
MECANISMO DE DOENÇA

Xanthinuria 1

A disorder characterized by excretion of very large amounts of xanthine in the urine and a tendency to form xanthine stones. Uric acid is strikingly diminished in serum and urine. XAN1 is due to isolated xanthine dehydrogenase deficiency. Patients can metabolize allopurinol.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
26.1 TPM
Intestino delgado
12.4 TPM
Esôfago - Mucosa
7.6 TPM
Cólon transverso
4.7 TPM
Glândula salivar
3.6 TPM
OUTRAS DOENÇAS (1)
xanthinuria type I
HGNC:12805UniProt:P47989
ADAAdenosine deaminaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine (PubMed:16670267, PubMed:23193172, PubMed:26166670, PubMed:8452534, PubMed:9361033). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (

LOCALIZAÇÃO

Cell membraneCell junctionCytoplasmic vesicle lumenCytoplasmLysosome

VIAS BIOLÓGICAS (2)
Purine salvageRibavirin ADME
MECANISMO DE DOENÇA

Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-negative due to adenosine deaminase deficiency

An autosomal recessive disorder accounting for about 50% of non-X-linked SCIDs. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. ADA deficiency has been diagnosed in chronically ill teenagers and adults (late or adult onset). Population and newborn screening programs have also identified several healthy individuals with normal immunity who have partial ADA deficiency.

OUTRAS DOENÇAS (2)
severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiencyOmenn syndrome
HGNC:186UniProt:P00813
UMPSUridine 5'-monophosphate synthaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme catalyzing the last two steps of de novo pyrimidine biosynthesis, orotate phosphoribosyltransferase (OPRT), which converts orotate to orotidine-5'-monophosphate (OMP), and orotidine-5'-monophosphate decarboxylase (ODC), the terminal enzymatic reaction that decarboxylates OMP to uridine monophosphate (UMP)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Pyrimidine biosynthesis
MECANISMO DE DOENÇA

Orotic aciduria 1

A disorder of pyrimidine metabolism resulting in megaloblastic anemia and orotic acid crystalluria that is frequently associated with some degree of physical and intellectual disability. A minority of cases have additional features, particularly congenital malformations and immune deficiencies.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
15.9 TPM
Fibroblastos
15.6 TPM
Esôfago - Mucosa
9.6 TPM
Skin Sun Exposed Lower leg
9.1 TPM
Skin Not Sun Exposed Suprapubic
8.5 TPM
OUTRAS DOENÇAS (1)
orotic aciduria
HGNC:12563UniProt:P11172
BLKTyrosine-protein kinase BlkDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling (By similarity). B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors (By similarity). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (By similarity). Signaling through BLK plays an important role in transmitting signals through surface immunog

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
RUNX1 regulates transcription of genes involved in BCR signaling
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 11

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

OUTRAS DOENÇAS (3)
maturity-onset diabetes of the young type 11systemic lupus erythematosusmaturity-onset diabetes of the young
HGNC:1057UniProt:P51451
INSInsulinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Insulin receptor recyclingSignaling by Insulin receptor
MECANISMO DE DOENÇA

Hyperproinsulinemia

An autosomal dominant condition characterized by elevated levels of serum proinsulin-like material.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pâncreas
2325.3 TPM
Glândula adrenal
0.5 TPM
Cervix Ectocervix
0.5 TPM
Substância negra
0.4 TPM
Baço
0.3 TPM
OUTRAS DOENÇAS (6)
maturity-onset diabetes of the young type 10diabetes mellitus, permanent neonatal 4hyperproinsulinemiatype 1 diabetes mellitus 2
HGNC:6081UniProt:P01308
LDHBL-lactate dehydrogenase B chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+)

LOCALIZAÇÃO

CytoplasmMitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Pyruvate metabolism
MECANISMO DE DOENÇA

Lactate dehydrogenase B deficiency

A condition with no deleterious effects on health. LDHBD is of interest to laboratory medicine mainly because it can cause misdiagnosis in those disorders in which elevation of serum LDH is expected.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1127.9 TPM
Coração - Ventrículo esquerdo
873.8 TPM
Rim - Medula
786.4 TPM
Fibroblastos
738.5 TPM
Rim - Córtex
622.3 TPM
OUTRAS DOENÇAS (1)
glycogen storage disease due to lactate dehydrogenase H-subunit deficiency
HGNC:6541UniProt:P07195
CELBile salt-activated lipaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the hydrolysis of a wide range of substrates including cholesteryl esters, phospholipids, lysophospholipids, di- and tri-acylglycerols, and fatty acid esters of hydroxy fatty acids (FAHFAs) (PubMed:10220579, PubMed:27509211, PubMed:27650499, PubMed:8471055). Preferentially hydrolyzes FAHFAs with the ester bond further away from the carboxylate. Unsaturated FAHFAs are hydrolyzed more quickly than saturated FAHFAs (By similarity). Has an essential role in the complete digestion of dietar

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Developmental Lineage of Pancreatic Acinar Cells
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 8 with exocrine dysfunction

An autosomal dominant form of diabetes characterized by a primary defect in insulin secretion, exocrine pancreatic dysfunction, altered pancreatic morphology, recurrent abdominal pain, and fecal elastase deficiency. Disease onset is at less than 25 years of age.

OUTRAS DOENÇAS (2)
maturity-onset diabetes of the young type 8maturity-onset diabetes of the young
HGNC:1848UniProt:P19835
KLF11Krueppel-like factor 11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor (PubMed:10207080, PubMed:9748269). Activates the epsilon- and gamma-globin gene promoters and, to a much lower degree, the beta-globin gene and represses promoters containing SP1-like binding inhibiting cell growth (PubMed:10207080, PubMed:16131492, PubMed:9748269). Represses transcription of SMAD7 which enhances TGF-beta signaling (By similarity). Induces apoptosis (By similarity)

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 7

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
43.6 TPM
Tecido adiposo
42.3 TPM
Adipose Visceral Omentum
38.4 TPM
Skin Not Sun Exposed Suprapubic
35.0 TPM
Mama
34.6 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (2)
maturity-onset diabetes of the young type 7maturity-onset diabetes of the young
HGNC:11811UniProt:O14901
PAX4Paired box protein Pax-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in the differentiation and development of pancreatic islet beta cells. Transcriptional repressor that binds to a common element in the glucagon, insulin and somatostatin promoters. Competes with PAX6 for this same promoter binding site. Isoform 2 appears to be a dominant negative form antagonizing PAX4 transcriptional activity

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells
MECANISMO DE DOENÇA

Type 2 diabetes mellitus

A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.3 TPM
Intestino delgado
0.3 TPM
Cólon transverso
0.2 TPM
Pâncreas
0.0 TPM
Linfócitos
0.0 TPM
OUTRAS DOENÇAS (4)
maturity-onset diabetes of the young type 9type 2 diabetes mellitusmaturity-onset diabetes of the youngdiabetes mellitus, ketosis-prone
HGNC:8618UniProt:O43316
HNF4AHepatocyte nuclear factor 4-alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes (PubMed:30597922). Activates the transcription of CYP2C38 (By similarity). Represses the CLOCK-BMAL1 transcriptional activity and is essential for circadian rhythm maintenance and period regulation in the liver and colon cells (PubMed:30530698)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Nuclear Receptor transcription pathwayNephron development
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 1

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
55.4 TPM
Cólon transverso
33.0 TPM
Intestino delgado
30.7 TPM
Rim - Córtex
11.4 TPM
Pâncreas
5.6 TPM
OUTRAS DOENÇAS (7)
maturity-onset diabetes of the young type 1Fanconi renotubular syndrome 4 with maturity-onset diabetes of the youngmonogenic diabetesatypical Fanconi syndrome-neonatal hyperinsulinism syndrome
HGNC:5024UniProt:P41235
KCNJ11ATP-sensitive inward rectifier potassium channel 11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells (PubMed:29286281, PubMed:34815345). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (6)
Ion homeostasisABC-family proteins mediated transportDefective ABCC9 causes CMD10, ATFB12 and Cantu syndromeDefective ABCC8 can cause hypo- and hyper-glycemiasRegulation of insulin secretion
MECANISMO DE DOENÇA

Hyperinsulinemic hypoglycemia, familial, 2

A form of hyperinsulinemic hypoglycemia, a clinically and genetically heterogeneous disorder characterized by inappropriate insulin secretion from the pancreatic beta-cells in the presence of low blood glucose levels. HHF2 is a common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. HHF2 inheritance can be autosomal dominant or autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
87.1 TPM
Cerebelo
37.4 TPM
Cérebro - Hemisfério cerebelar
36.8 TPM
Córtex cerebral
14.0 TPM
Brain Frontal Cortex BA9
13.9 TPM
OUTRAS DOENÇAS (12)
maturity-onset diabetes of the young type 13diabetes mellitus, permanent neonatal 2hyperinsulinemic hypoglycemia, familial, 2diabetes mellitus, transient neonatal, 3
HGNC:6257UniProt:Q14654

Variantes genéticas (ClinVar)

288 variantes patogênicas registradas no ClinVar.

🧬 PDX1: NM_000209.4(PDX1):c.851G>A (p.Ter284=) ()
🧬 PDX1: NM_000209.4(PDX1):c.533A>C (p.Glu178Ala) ()
🧬 PDX1: NM_000209.4(PDX1):c.784C>A (p.Pro262Thr) ()
🧬 PDX1: NM_000209.4(PDX1):c.54C>A (p.Cys18Ter) ()
🧬 PDX1: NM_000209.4(PDX1):c.494_497delinsAC (p.Phe165fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

76 vias biológicas associadas aos genes desta condição.

Regulation of gene expression in beta cells Regulation of gene expression in early pancreatic precursor cells Developmental Lineage of Pancreatic Acinar Cells Developmental Lineage of Pancreatic Ductal Cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells Purine ribonucleoside monophosphate biosynthesis Purine salvage Platelet degranulation Neutrophil degranulation Glycolysis Gluconeogenesis Pyrimidine catabolism Pyrimidine salvage Caspase activation via Dependence Receptors in the absence of ligand Mitochondrial tRNA aminoacylation Interconversion of nucleotide di- and triphosphates TP53 Regulates Metabolic Genes ATP sensitive Potassium channels Regulation of insulin secretion Defective ABCC8 can cause hypo- and hyper-glycemias Synthesis of GDP-mannose Defective HK1 causes hexokinase deficiency (HK deficiency) ChREBP activates metabolic gene expression Pyruvate metabolism SARS-CoV-1-host interactions Signaling by ALK fusions and activated point mutants Peptide ligand-binding receptors G alpha (i) signalling events RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX1 regulates transcription of genes involved in differentiation of HSCs Factors involved in megakaryocyte development and platelet production Defective APRT disrupts adenine salvage Manipulation of host energy metabolism Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells Nephron development Molybdenum cofactor biosynthesis Asparagine N-linked glycosylation Defective HPRT1 disrupts guanine and hypoxanthine salvage Azathioprine ADME Purine catabolism Ribavirin ADME Resolution of AP sites via the single-nucleotide replacement pathway APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway HDR through MMEJ (alt-NHEJ) Gap-filling DNA repair synthesis and ligation in GG-NER Gap-filling DNA repair synthesis and ligation in TC-NER Strand-asynchronous mitochondrial DNA replication Defective GCK causes maturity-onset diabetes of the young 2 (MODY2) FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Apoptosis induced DNA fragmentation Mitochondrial protein import Mitochondrial protein degradation Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells Regulation of pyruvate metabolism 5-Phosphoribose 1-diphosphate biosynthesis Butyrophilin (BTN) family interactions Defective ADA disrupts (deoxy)adenosine deamination Pyrimidine biosynthesis RUNX1 regulates transcription of genes involved in BCR signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Insulin processing Synthesis, secretion, and deacylation of Ghrelin COPI-mediated anterograde transport PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling NPAS4 regulates expression of target genes Amyloid fiber formation Digestion of dietary lipid Nuclear Receptor transcription pathway ABC-family proteins mediated transport Ion homeostasis Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
2Fase 21
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença do metabolismo das purinas ou pirimidinas

Centros de Referência SUS

21 centros habilitados pelo SUS para Doença do metabolismo das purinas ou pirimidinas

Centros para Doença do metabolismo das purinas ou pirimidinas

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Pentose phosphate pathway fuels cGAS-STING signalling to boost function of intratumoral conventional dendritic cells.

Nature communications2026 Mar 23

Este artigo revela que os tumores comprometem a capacidade das células imunes (células dendríticas) de combater o câncer ao reduzir uma via metabólica crucial chamada via das pentoses-fosfato (PPP). Essa via é essencial porque impulsiona o metabolismo de purinas (como ATP e GTP), que ativa uma importante sinalização (cGAS-STING) fortalecendo a resposta imune antitumoral. Aumentar a atividade da PPP nessas células pode restaurar sua função, melhorar a eficácia da imunoterapia – especialmente em combinação com bloqueadores de PD-L1 – e oferece uma promissora nova estratégia para o tratamento do câncer.

🇧🇷 traduzido
#2

The m5C orchestrator NSUN7 drives SPARC/HMGB1 axis-mediated inflammation to exacerbate kidney injury.

Proceedings of the National Academy of Sciences of the United States of America2026 Mar 31

Este estudo identifica a enzima NSUN7 como um impulsionador crucial da inflamação e lesão renal, especialmente na Lesão Renal Aguda (LRA), ao promover modificações específicas no RNA que amplificam a resposta inflamatória. A inibição de NSUN7 demonstrou reduzir a inflamação e melhorar os resultados renais; e uma nova terapia que silencia NSUN7 com um sistema de entrega específico para o rim mostrou-se eficaz em modelos de LRA, indicando-o como um promissor alvo terapêutico para doenças renais inflamatórias.

🇧🇷 traduzido
#3

Reassessing Transketolase Assays: Methodological Considerations for Detecting Functional Thiamine Deficiency.

Annals of the New York Academy of Sciences2026 Mar

A deficiência de tiamina (vitamina B1) é uma condição prevalente. Este artigo foca em aprimorar o ensaio de transketolase (TKT), um teste que mede a funcionalidade da tiamina, para além de apenas detectar a deficiência. Para pacientes e médicos, uma melhor metodologia permite distinguir se a causa é a falta da vitamina ou um problema na sua utilização pela enzima, oferecendo um diagnóstico mais preciso e orientando tratamentos mais eficazes.

🇧🇷 traduzido
#4

Brain neuronal CG9593/ANGPTL4 activation mediates paternally acquired motor disorders.

Science advances2026 Mar 20

O título e resumo fornecidos não se referem a "Desordens do metabolismo de purinas ou pirimidinas", mas sim a **"Ativação neuronal cerebral CG9593/ANGPTL4 medeia distúrbios motores adquiridos paternalmente"**. Focando no conteúdo deste artigo específico: Este estudo revela que a exposição ambiental paterna a metais pesados pode levar a distúrbios motores progressivos e perda de neurônios dopaminérgicos em múltiplas gerações da prole. A proteína ANGPTL4 no cérebro é identificada como mediadora crucial deste processo, com níveis séricos em humanos correlacionados negativamente com a função motora pediátrica. Isso aponta a ANGPTL4 como um potencial alvo terapêutico promissor para transtornos motores hereditários influenciados por fatores paternos.

🇧🇷 traduzido
#5

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Science advances2026 Mar 20

Este estudo em Leucemia Mieloide Crônica (LMC) revela que o tratamento com imatinib provoca, em apenas uma hora, um rápido aumento na "leitura transcricional" (readthrough), um processo que leva à formação de novas moléculas de RNA, incluindo "quimeras de readthrough". Essas alterações moleculares precoces, detectadas em pacientes e em células resistentes ao imatinib, sugerem um mecanismo fundamental pelo qual a terapia pode iniciar ajustes genéticos que contribuem para o desenvolvimento de resistência ao tratamento.

🇧🇷 traduzido

Publicações recentes

📚 EuropePMCmostrando 200

2026

Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity.

The Journal of infectious diseases
2026

Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model.

The Journal of antimicrobial chemotherapy
2026

Geraniol Mitigates Cytarabine-Induced Hepatotoxicity in Mice via PI3K/AKT-Mediated NRF2 Activation.

Journal of biochemical and molecular toxicology
2026

[Efficient conversion of cytidine to synthesize cytidine 5{L-End} '-monophosphate based on the ATP regeneration system].

Sheng wu gong cheng xue bao = Chinese journal of biotechnology
2026

Pentose phosphate pathway fuels cGAS-STING signalling to boost function of intratumoral conventional dendritic cells.

Nature communications
2026

Perturbation of azurophilic granule integrity drives NLRP3-independent IL-1β processing and release in neutrophils.

Journal of immunology (Baltimore, Md. : 1950)
2026

The m5C orchestrator NSUN7 drives SPARC/HMGB1 axis-mediated inflammation to exacerbate kidney injury.

Proceedings of the National Academy of Sciences of the United States of America
2026

The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.

Journal of visualized experiments : JoVE
2026

Efficacy of Lithium Carbonate Combined with Olanzapine, Risperidone, or Quetiapine in Bipolar Disorder Treatment and Effects on Glycolipid Metabolism.

Journal of visualized experiments : JoVE
2026

METTL3-mediated TIGAR m6A modification and its role in microglia activation related to Alzheimer's disease.

Neuroreport
2026

Reassessing Transketolase Assays: Methodological Considerations for Detecting Functional Thiamine Deficiency.

Annals of the New York Academy of Sciences
2026

Dynamic regulation of mRNA acetylation at synapses by spatial memory in mouse hippocampus.

eLife
2026

Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1.

JCI insight
2026

From soluble uric acid to sodium urate crystal: immune metabolic inflammation driven by uric acid morphological transformation and mechanism-oriented therapy.

Frontiers in immunology
2026

Formulation and Physicochemical Characterization of Capecitabine-Loaded Cubosomes for Enhanced Drug Delivery System.

Drug design, development and therapy
2026

The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway.

Drug design, development and therapy
2026

Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Drug design, development and therapy
2026

Pyrimidine nucleoside: inspiration for novel antimicrobial agent.

Frontiers in pharmacology
2026

Discovery of pyrimidine-based small activators of insulin degrading enzyme.

European journal of medicinal chemistry
2026

Brain neuronal CG9593/ANGPTL4 activation mediates paternally acquired motor disorders.

Science advances
2026

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.

Science advances
2026

Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.

Proceedings of the National Academy of Sciences of the United States of America
2026

Efficacy of Nebulized Pentoxifylline in a Mouse Model of Emphysema Induced by Cigarette Smoke and Aerosolized Lipopolysaccharide.

International journal of chronic obstructive pulmonary disease
2026

The Cross-Species Implantable ATP Battery Inspired by Photosynthesis for Application in Diseases.

International journal of nanomedicine
2026

Combinatorial Anti-Mitotic Activity of Loratadine/5-Fluorouracil Loaded Zein Tannic Acid Nanoparticles in Breast Cancer Therapy: In silico, in vitro and Cell Studies.

International journal of nanomedicine
2026

Histone lactylation-driven feedback loop modulates pyrimidine metabolism to promote oral carcinogenesis.

Cell death & disease
2026

Pregnancy-Specific Reference Intervals for Maternal Biochemical Parameters and Associations With Adverse Pregnancy Outcomes in a Japanese Cohort.

The journal of obstetrics and gynaecology research
2026

Chronic Gastric Ulceration Due to Cytomegalovirus in Immunocompetent Adults - A Case Report and Systematic Review.

Reviews in medical virology
2026

The relationship between the atherogenic index of plasma and hyperuricemia in American adults aged over 20 years: A cross-sectional study.

PloS one
2026

RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma.

Cancer immunology, immunotherapy : CII
2026

The effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia.

Stem cell research & therapy
2026

A Case of Wernicke's Encephalopathy in the Second Trimester of a Woman With Super-Super Obesity and a Monochorionic Diamniotic Twin Pregnancy.

The journal of obstetrics and gynaecology research
2026

Sexual dimorphism in liver fibrotic metabolic dysfunction: Effects of testosterone and estrogen on CCl4-induced liver injury in ovariectomy and orchiectomy models.

The Journal of steroid biochemistry and molecular biology
2026

FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Cell reports. Medicine
2026

The effect of HFE gene mutation and iron overload on sustained virological response in Egyptian chronic hepatitis C patients treated with daclatasvir and sofosbuvir.

The Korean journal of internal medicine
2026

Thiamine status of whitefish (Coregonus maraena) in the Baltic Sea.

PloS one
2026

Oral supplementation of Pediococcus pentosaceus SMM847 ameliorates hyperuricemia in rats and alcohol-induced injury in mice.

Applied and environmental microbiology
2026

Cytomegalovirus Infection Mimics Manifestations of Underlying Diseases in Patients With Autoimmune Disorders: A Case Report and Literature Review.

Immunity, inflammation and disease
2026

Uric acid and hyperuricemia in relation to non-alcoholic fatty liver disease among individuals with type 2 diabetes: insights from a cross-sectional analysis.

Frontiers in endocrinology
2026

Identification and Validation of Key Purine Metabolism-Related Genes in Ulcerative Colitis Using Bioinformatics and Machine Learning.

Journal of inflammation research
2026

Allopurinol and Febuxostat Hypersensitivity in a Patient with Young Onset Gout: A Case Report.

Acta medica Philippina
2026

[The Relationship between OPN, NLR and Chemotherapy Efficacy in Patients with Acute Myeloid Leukemia].

Zhongguo shi yan xue ye xue za zhi
2026

Progress on N4-acetylcytidine in animal reproductive development.

Yi chuan = Hereditas
2026

Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles.

Clinical and translational science
2026

Mechanism underlying the inhibitory effects of nonanoic acid on Phytophthora capsici: Insights from integrated transcriptomic and metabolomic analyses.

Pest management science
2026

Treatment-free remission in MS: long-term disease control with cladribine tablets.

Journal of neurology
2026

M6A-modified circArhgap26 attenuates cardiac ischemia‒reperfusion injury by suppressing plakophilin-1 palmitoylation.

Signal transduction and targeted therapy
2026

Inosine promotes erythrocyte metabolic reprogramming and restores oxygen release for rejuvenation via 2,3-BPG-PNP axis.

Cell discovery
2026

Beta-Amyloid Suppresses Mitochondrial ATP Production in Human Neuroblastoma Cells.

Biochemistry. Biokhimiia
2026

ML364 ameliorates NLRP3-induced inflammatory response.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2026

Systems Biology of Metabolic Dysregulation in Ankylosing Spondylitis Using scRNA-Seq Data.

Omics : a journal of integrative biology
2026

De novo transcriptome analysis in response to yellow vein mosaic virus disease in okra (Abelmoschus esculentus L.).

Physiology and molecular biology of plants : an international journal of functional plant biology
2026

Transcriptomic and metabolomic profiling reveals media- and host-dependent responses to Staphylococcus hominis in cell models.

PeerJ
2026

ALKBH5-Driven m6A Demethylation Boosts Inflammation and Autophagy in LPS-Stimulated Macrophages.

Immunity, inflammation and disease
2026

Transcriptomics and metabolomics reveal functional nanoplastics-induced male reproductive damage and resveratrol antagonistic effects.

Journal of nanobiotechnology
2026

Polymer-Surfactant Stabilized Amorphous Nanosuspension of Pazopanib: Box-Behnken Optimization and In-vivo Evaluation.

AAPS PharmSciTech
2026

Sspdhx Related to the Development and Virulence of Sclerotinia sclerotiorum Represents a Potential RNAi Target for Controlling Sclerotinia Disease.

Molecular plant pathology
2026

Integrated transcriptomic and metabolomic analysis reveals the molecular mechanisms underlying perfluorooctanoic acid (PFOA)-induced developmental toxicity during the early life stages of Paralichthys olivaceus.

Environmental pollution (Barking, Essex : 1987)
2026

Hippocampal energy metabolism reprogramming underlies individual differences in paroxetine-facilitated contextual fear extinction.

Behavioural brain research
2026

Enhanced Delivery of Aurora Kinase A Inhibitor Alisertib via Tumor-Targeting Immunoliposome Nanocomplex for Improved Treatment of Cancers Including Atypical Teratoid/Rhabdoid Tumor.

International journal of nanomedicine
2026

Spatiotemporal immune gradients in gout: immune response-driven activation of the NLRP3-IL-1β axis and its transition to trained immunity.

Frontiers in immunology
2026

DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs.

Frontiers in cell and developmental biology
2026

Nucleoside Analogue with Thymidine Nucleobase Inhibits Leishmania infantum and Depolarizes the Plasma Membrane Potential In Vitro.

ACS omega
2026

Cell-Type-Specific WTAP and ALKBH5-Mediated m6A Methylation Orchestrates Mental Disorders via Gut-Brain Axis Metabolite Signaling: Multi-Omics Evidence and Pyroptosis-Associated Loop Mechanism.

CNS neuroscience & therapeutics
2026

INSIG1/2 succination mediated by the moonlighting function of ADSL promotes lipogenesis and liver tumorigenesis.

Nature communications
2026

A Systematic Review of Clinically Significant Drug-Drug Interactions With Phenobarbital and Primidone.

Pharmacotherapy
2026

Unraveling the Link Between Azathioprine and Acute Pancreatitis: Integrating Network Toxicology, Machine Learning, and Mendelian Randomization.

CPT: pharmacometrics & systems pharmacology
2026

Elucidating the Anti-thrombotic Mechanism of Equiseti hiemalis Herba through Integrated Pharmacology.

Current pharmaceutical design
2026

Self-expanding sodium alginate sulfate drug-loaded microspheres for stabilized arterial embolization.

Carbohydrate polymers
2026

Design and synthesis of mesoionic compounds containing benzoxacycle for the control of piercing-sucking pests.

Pesticide biochemistry and physiology
2026

Metabolic Tracing Reveals IL-2 Driven Glutaminolysis and De Novo Pyrimidine Synthesis in Human Natural Killer Cells.

The Journal of biological chemistry
2026

B cell receptor stimulation inhibits class switch recombination through elevated DNA repair.

DNA repair
2026

Interaction of Fluoxetine and Caffeine in a Patient With Substance-Induced Mania.

Bipolar disorders
2026

γδTreg/γδTh17 Cell Imbalance Drives Xanthine-Mediated Metabolic Dysfunction in Restraint Stress-Induced Anxiety-Like Behavior.

Cell biology international
2026

Antithrombotic Effects of Cordycepin-Enriched WIB-801CE via Inhibition of Thromboxane A2-Induced αIIbβ3 Activation and Thrombin-Mediated Fibrin Clot Retraction.

International journal of molecular sciences
2026

Administration of Nicotinamide Mononucleotide Mitigates the HIV Nef-Induced Metabolic and Pathological Changes in the Heart.

Cells
2026

Impaired Acetyl-CoA Compartmentalization Drives a Futile Lipogenic-Oxidative Cycle in N88S Seipinopathy.

Cells
2026

Metabolic Myopathies and HyperCKemia in Adulthood: A Clinical Approach to Diagnosis and Management.

Journal of clinical medicine
2026

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.

Cancer chemotherapy and pharmacology
2026

A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.

The pharmacogenomics journal
2026

Exploiting Metabolic Dependencies for Therapeutic Targeting of Brain Cancers.

Cancer letters
2026

Deletion of vitamin D receptor with calcium sensing receptor in keratinocytes promotes epidermal tumorigenesis by limiting dna repair and oxidative stress response genes.

The Journal of steroid biochemistry and molecular biology
2026

Identification of mitochondrial dynamics-related biomarkers in psoriasis using bioinformatics and Mendelian randomization.

Medicine
2026

Essential role of cytochrome bc 1 in Pseudomonas aeruginosa cell physiology and virulence.

Frontiers in cellular and infection microbiology
2025

Growth Characteristics, Blood Biochemistry, Histology, and Metabolic Profile of Muscle and Different Tissues: Toxicity Study of Deoxynivalenol.

Food science of animal resources
2026

Adenine phosphoribosyltransferase deficiency and 2,8-dihydroxyadeninuria.

Pediatric nephrology (Berlin, Germany)
2026

Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy.

Signal transduction and targeted therapy
2026

Seasonal trade-offs shape metabolomic and proteomic responses to Varroa destructor parasitisation in honey bees (Apis mellifera).

Insect biochemistry and molecular biology
2026

Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.

Cell
2026

Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-Like Pancreatic Cancer.

Cancer research
2026

Susceptibility to columnaris disease in Chinook salmon Oncorhynchus tshawytscha offspring from thiamine-deficient and thiamine-replete females.

Diseases of aquatic organisms
2026

Contribution of adenosine A2A receptor agonist and antagonist on ovarian ischemia/reperfusion injury in rats.

Turkish journal of medical sciences
2026

Differential in vitro and in vivo responses of Akkermansia muciniphila to Odontosoria biflora (Kaulf.) C.Chr. [Lindsaeaceae] hexane extract in diet- and alloxan-induced BALB/c mice.

Acta biochimica Polonica
2026

cAMP/PKA signaling in endocrine hypertension: genetic mechanisms and pathophysiological insights.

Frontiers in endocrinology
2026

L-Glutamine attenuates peritoneal fibrosis developed in 5-Fluorouracil-treated mice.

Experimental biology and medicine (Maywood, N.J.)
2026

Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure.

Cell reports. Medicine
2026

Discovery of a pyrimidine-based steroidal FXR agonist for the treatment of metabolic dysfunction-associated steatotic liver disease.

Bioorganic chemistry
2026

PAICS mediates DNA damage and cerebellar neuronal loss in C9orf72 amyotrophic lateral sclerosis.

Brain : a journal of neurology
2026

Xinlikang Capsule Alleviates Chemotherapy-Induced Fatigue by Inhibiting the PI3K/AKT-mTOR-FoxO Pathway.

Analytical cellular pathology (Amsterdam)
2026

Translational regulation by oxidative desulfuration of tRNA modifications.

Nature communications
2026

Roseburia inulinivorans increases muscle strength.

Gut
2026

Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery.

Cell reports. Medicine
2026

Transcriptome analysis coupled with virus induced gene silencing delineates the unfolded protein response of tomato.

Molecular genetics and genomics : MGG
2026

Orn-mediated c-di-GMP regulates the CRISPR-Cas system to confer stress response in Mycobacterium tuberculosis.

Nucleic acids research
2026

Ceritinib Induces Mitochondrial Fragmentation in Thyroid Cancer Cells by Targeting Drp-1.

Drug development research
2026

Extracellular Polysaccharides of Eurotium cristatum from Fu Brick Tea Ameliorated Type 2 Diabetes in Mice by Remodeling of Gut Microbiota-Dependent Tryptophan Metabolism to Activate the Hepatic AhR/TSC2/mTORC1 Axis.

Journal of agricultural and food chemistry
2026

5-Aza-Cytidine Enhances Terminal Polyadenylation Site Usage for Full-Length Transcripts in Cells.

Genes to cells : devoted to molecular & cellular mechanisms
2026

Portal Vein Tryptophan Pathway Analysis Reveals Gut-Mediated Inflammatory Pathway Predominance in HCV Infection.

Liver international : official journal of the International Association for the Study of the Liver
2026

CDH1, CAV1, NR3C1, and ZEB1 are Potential Biomarkers in Colorectal Cancer Drug Resistance and Prognosis.

Technology in cancer research & treatment
2026

Longitudinal, Multicenter Study of Clinical Factors Impacting Health-Related Quality of Life in Paediatric Autoimmune Liver Disease.

Liver international : official journal of the International Association for the Study of the Liver
2026

A real-world retrospective cohort study comparing brand-name febuxostat (feburic) and generic febuxostat (feuri).

Science progress
2026

SEVERE TOXIC EPIDERMAL NECROLYSIS COMPLICATED BY ACUTE KIDNEY INJURY: DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS.

Georgian medical news
2026

Sex Differences in Metabolite-Immune Circuits of Neuroinflammation.

Immunological reviews
2026

Protective Effects of Pentoxifylline on Peripheral Microcirculatory Dysfunction and Renal Cortical Oxygen Deficiency in a Rat Model of LPS-Induced Sepsis.

Microcirculation (New York, N.Y. : 1994)
2026

Gegen Qinlian decoction alleviates bacterial diarrhea via Lactobacillus amylovorus-modulated restoration of colonic water transport through the cAMP/CFTR/AQP3 pathway.

Microbial pathogenesis
2026

Impact of macrophages on the dissolution of LAI suspension prodrugs.

International journal of pharmaceutics
2026

Habitual coffee consumption poorly correlates with sleep quality and daytime sleepiness: A cross-sectional study.

PloS one
2026

Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis.

Cardiovascular toxicology
2026

Ketone Body Supplementation Exerts Renoprotective Effects Against Adenine-Induced Kidney Injury via OXCT1-Mediated Ketolysis in Mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Advances in artificial metabzymes for macrophage polarization in tumor metabolic immunotherapy.

Materials today. Bio
2026

Development and Validation of an HPLC-MS/MS Method for Pharmacokinetic Evaluation of Tofacitinib/Simvastatin Compound Ointment in Rats.

Drug design, development and therapy
2026

Small metabolites vary in sow milk across the course of lactation, while moringa supplementation and cooling sows exposed to heat stress conditions have limited effects.

Translational animal science
2026

Globo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway.

Theranostics
2026

Multi-omics analysis reveals the mechanism of verbenalin in treating gout via modulating purine metabolism, gut microbiota, and inflammatory pathways.

Frontiers in immunology
2026

Integrating network pharmacology, microbiomics, and metabolomics to uncover the therapeutic effect of Liubao tea on osteoarthritis.

Frontiers in immunology
2026

Deep learning model and omics screening highlight angiotensinogen as a 5-methylcytosine (m5C) regulated mediator of tumor-microenvironment communication in liver cancer.

Frontiers in immunology
2026

Relation of serum uric acid with the risk of coronary heart disease: an updated systematic review and dose-response meta-analysis of epidemiologic studies.

Frontiers in endocrinology
2026

Evaluation of IL-1β, 8-OHdG and TBARS in Autistic Children: The Role of Inflammatory Biomarkers.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2026

Regulation of Cellular Signaling by CUL5 is Dependent on Its Neddylation Status.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
2025

Clinical outcomes and safety study of CDK4/6 inhibitors in hormone-positive metastatic breast cancer - A real-world tertiary cancer center experience.

Indian journal of cancer
2026

Xiayuxue decoction alleviates MASH by regulating gut microbiota, bile acid metabolism, and m6A modification.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Serum metabolomics coupled with HR-VWI radiomics reveals metabolic alterations in asymptomatic carotid artery stenosis.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
2026

Activity-tunable bimetallic iron-cobalt nanoflowers integrated with smartphones for rapid detection of human uric acid.

Analytica chimica acta
2026

Curcumin Modulates 5-fluorouracil Sensitivity in Colorectal Cancer Cells Through the circ-NRIP1/miR-195-5p/SMURF1/AKT Signaling Axis.

Journal of biochemical and molecular toxicology
2026

The potential role of adenosinergic pathway and methylxanthines in Parkinson's disease: Blowing in the wind or not.

Purinergic signalling
2026

Structural and Functional Diversity of Mitochondria Isolated from Different Cell Types.

Biological & pharmaceutical bulletin
2026

Identification of Novel Oxazolo[5,4-d]pyrimidines as IL-33 Inhibitors for Immuno-Oncology Therapy.

Chembiochem : a European journal of chemical biology
2026

Exploring the behavioural and biochemical effects of cordycepin in PTSD-like behaviour using an early life stress mouse model.

Biochemical and biophysical research communications
2026

Impact of risperidone and voluntary exercise on ketone body metabolism-related gene expression in the brain of female juvenile rats.

Behavioural brain research
2026

Impact of sulfamethoxazole, trimethoprim, diclofenac, carbamazepine, and their mixture on the metabolism of Lemna minor: a targeted metabonomic study.

Metabolomics : Official journal of the Metabolomic Society
2026

Targeting amino acid metabolic pathways: a novel therapeutic strategy for hyperuricemia-associated complications.

Amino acids
2026

Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.

The American journal of case reports
2026

Ecotoxicity of ultraviolet radiation on ciliates: Population growth, DNA damage and photooxidative stress.

European journal of protistology
2026

Differential modulation of haematopoietic and oxidative injury by PARP-1 and ATR kinase inhibition in a murine model of acute irradiation.

PloS one
2026

Hypomorphic mutations in ura6 confer 5-FOA resistance in fission yeast.

PloS one
2026

A bioinformatics and experimental study toward new therapeutic strategies: CXCL8 in gout progression.

Medicine
2026

NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.

Cancer chemotherapy and pharmacology
2026

Identification of FTO as a key m6A demethylase linking immune dysregulation to sepsis pathogenesis.

Frontiers in immunology
2026

N6-adenosine methylation enhances nuclear mRNA export through METTL3 and NUP93.

Nature cell biology
2026

ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer.

Oncogene
2026

Chitosan-functionalized Cu-doped NiO/reduced graphene oxide nanocarrier for pH-triggered delivery of 5-fluorouracil in breast cancer cells.

International journal of biological macromolecules
2026

α-asaronol alleviates seizures, neuroinflammation and cognitive deficits in a mice model of lithium-pilocarpine-induced seizures.

Journal of ethnopharmacology
2026

An ex vivo functional biomarker of treatment response in pediatric low-grade glioma.

PloS one
2026

COL8A1-positive cancer-associated fibroblasts are drivers of 5-fluorouracil resistance in colorectal cancer.

Apoptosis : an international journal on programmed cell death
2026

Opening of rod photoreceptor CNG channels by photodynamically generated singlet oxygen.

The Journal of general physiology
2026

What kills a society: accumulation of uric acid increases infectious disease risk in termites.

Proceedings. Biological sciences
2026

Neuropilin-2 Deficiency Promotes Mitochondrial Dysfunction and NAD⁺-Dependent Cellular Senescence in Retinal Degeneration.

Investigative ophthalmology & visual science
2025

A novel method for rapid determination of risperidone in human plasma using Reversed-Phase Liquid Chromatography with Ultra-Violet detection.

La Tunisie medicale
2026

Acquired Immunodeficiency in Newborn Following Intrauterine Exposure to Thiopurines for Treatment of Inflammatory Bowel Disease.

ACG case reports journal
2026

[Autosomal dominant dyskinesia associated with the ADCY5 gene].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2026

Quantum Chemical Properties of Fluorouracil/XZn11O12 (X = Zn, Cu, Fe, Ni) Nanocomplexes and Interactions with Human Serum Albumin.

ChemistryOpen
2026

A STING signaling relay from tumor cells to macrophages mediates the improved efficacy of combination chemotherapy in pancreatic cancer.

Journal of biomedical science
2026

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial.

Nature communications
2026

Dual metabolic reprogramming by metal-polyphenol nanoplatform enhances ferroptotic therapy for triple-negative breast cancer.

Journal of colloid and interface science
2026

Single-cell combined transcriptome explores the molecular mechanism of purine metabolism in keloids.

Burns : journal of the International Society for Burn Injuries
2026

Exploring novel management options for alopecia areata.

The American journal of managed care
2026

Recyclable Polymerizable Deep Eutectic Solvent-Based Three-Dimensional-Printed Dissolving Microneedles with pH-Responsive Delivery of ZIF-8-Loaded Minoxidil for Hair Loss Therapy.

ACS applied materials & interfaces
2026

Inhibition of FicD-mediated AMPylation and deAMPylation by isoprenoid diphosphates.

Proceedings of the National Academy of Sciences of the United States of America
2026

Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata.

Journal of drugs in dermatology : JDD
2026

Updates on Therapeutic Approaches for Management of Androgenetic Alopecia: A Review.

Journal of drugs in dermatology : JDD
2026

Serum biomarkers for predicting Crohn's disease activity: The role of bilirubin, uric acid, and the C-reactive protein/albumin ratio.

PloS one
2026

Emerging roles of RNA N5-methylcytosine modification in reproductive physiology and gynecological diseases.

Epigenetics
2025

[Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance 
in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics].

Zhongguo fei ai za zhi = Chinese journal of lung cancer
2026

N6-Methylation Modification: Its Role in Regulating Cell Senescence and Inflammation in Osteoarthritis and Intervertebral Disc Degeneration.

DNA and cell biology
2026

ATP bioenergetics and fatigue in young adults with and without major depression.

Translational psychiatry
2026

METTL3-Mediated m6A Regulation of CircINTS4/miR-146b-3p Axis in Rheumatoid Arthritis.

Inflammation
2026

Pyrimidine biosynthesis repression fuels cost and survival of trimethoprim/sulfamethoxazole - Resistant E. coli.

Journal of hazardous materials
2026

The multi-barrier fate of strobilurin fungicides in Dendrobium officinale: uptake, sequestration in root cell walls, and high cumulative dietary risk.

Ecotoxicology and environmental safety
2026

Marek's disease virus hijacks host nucleotide metabolism via UL23-mediated c-Myc activation.

Veterinary microbiology
2026

CapeOx -HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A multicenter propensity score-matched analysis.

Surgical oncology
2026

Phthalates exposure and serum uric acid level in patients with Crohn's disease: A cross-sectional study.

PloS one
2026

Trimethoprim: bactericidal or bacteriostatic activity is dependent on bacterial growth conditions.

Journal of medical microbiology
2026

The Tale of the Guanosine Tract in Repeat Expansion Disorders.

Molecular neurobiology
2026

Sequentially activated fluorescent probes based on a purine scaffold: enabling precise spatiotemporal monitoring of H2O2 and tyrosine hydroxylase in the brainstem NTS during spontaneous hypertension.

The Analyst
2026

Design, Synthesis, In Vitro and In Vivo Biological Evaluation of Novel Pyrazolo[3,4-d]Pyrimidine-Based Derivatives as Promising Multitarget Candidates for Alzheimer's Disease.

Drug development research
2026

Li-BrU-seq: A Low-Input and Simplified Metabolic Labeling Method for Nascent RNA Sequencing.

ACS chemical biology
2026

Preliminary Evidence for the Association of APOB rs1042034 With Short-Term Statin-Induced Lipid Lowering: An Exploratory Study in Vietnam.

Journal of cardiovascular pharmacology and therapeutics
2026

Network Pharmacology-Based Exploration: Non-Targeted Metabolites of Lactobacillus-Fermented Chaenomeles speciosa (Sweet) Nakai, Smilax glabra Roxb. and Pueraria montana var. Lobata in Uric Acid Metabolism Intervention.

Biologics : targets & therapy
2026

FUS is an N1- and N6-methyladenosine-binding protein.

Nucleic acids research
2026

Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV.

Diabetes & metabolism
2026

Association among serum uric acid, hyperactivity, impulsivity and dietary components in adults: a cross-sectional study Uric acid, hyperactivity/impulsivity symptoms, and dietary components in adults.

PloS one
2026

Rational design of a chitosan-coated cobalt ferrite nanozyme coupled with a molecularly imprinted polymer for trace analysis of buspirone in complex matrices: application in spiked human plasma and environmental water samples.

Analytical methods : advancing methods and applications
2026

FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine de novo synthesis.

Emerging microbes & infections
2026

Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability.

Cancer research communications
2026

In vivo inhibition of JAK-STAT signalling enhances high pathogenicity influenza virus replication in ducks.

The Journal of general virology
2026

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity.

Cancer immunology, immunotherapy : CII
2025

RAS-Related C3 Botulinum Toxin Substrate 1 Inhibition Attenuates Platelet Chemokine Activation in Diabetes Mellitus.

Archives of Razi Institute
2026

Gene Expression, Docking and Machine Learning in Malaria Drug Discovery: A Systematic Review.

Biochemistry research international
2026

Uric acid-to-albumin ratio as a cardiometabolic marker for predicting adverse outcomes in patients with atrial fibrillation: evidence from two independent cohorts.

Frontiers in endocrinology
2026

The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications.

Frontiers in immunology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença do metabolismo das purinas ou pirimidinas.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença do metabolismo das purinas ou pirimidinas

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Pentose phosphate pathway fuels cGAS-STING signalling to boost function of intratumoral conventional dendritic cells.
    Nature communications· 2026· PMID 41872210mais citado
  2. The m5C orchestrator NSUN7 drives SPARC/HMGB1 axis-mediated inflammation to exacerbate kidney injury.
    Proceedings of the National Academy of Sciences of the United States of America· 2026· PMID 41871257mais citado
  3. Reassessing Transketolase Assays: Methodological Considerations for Detecting Functional Thiamine Deficiency.
    Annals of the New York Academy of Sciences· 2026· PMID 41870883mais citado
  4. Brain neuronal CG9593/ANGPTL4 activation mediates paternally acquired motor disorders.
    Science advances· 2026· PMID 41861009mais citado
  5. Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib.
    Science advances· 2026· PMID 41860998mais citado
  6. The Regimen of Cladribine, Cytarabine, and Venetoclax (CAV) Induces Apoptosis in Acute Myeloid Leukemia Cells by Enhancing DNA Damage.
    J Vis Exp· 2026· PMID 41871015recente
  7. METTL3-mediated TIGAR m6A modification and its role in microglia activation related to Alzheimer's disease.
    Neuroreport· 2026· PMID 41870902recente
  8. Dynamic regulation of mRNA acetylation at synapses by spatial memory in mouse hippocampus.
    Elife· 2026· PMID 41870036recente
  9. Targeting PI3Kγ anchoring enhances CFTR membrane localization and modulator efficacy via PKD1.
    JCI Insight· 2026· PMID 41869727recente
  10. From soluble uric acid to sodium urate crystal: immune metabolic inflammation driven by uric acid morphological transformation and mechanism-oriented therapy.
    Front Immunol· 2026· PMID 41869323recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:79224(Orphanet)
  2. MONDO:0019254(MONDO)
  3. GARD:18980(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Q3281375(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Doença do metabolismo das purinas ou pirimidinas

ORPHA:79224 · MONDO:0019254
MedGen
UMLS
C0029595
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades